The effect of recombinant PTH(1-34) and PTH(1-84) on serum ionized calcium, 1,25-dihydroxyvitamin D, and urinary calcium excretion: a pilot study.

Piemonte S, Romagnoli E, Cipriani C, Fassino V, Del Fiacco R, Carnevale V, Scillitani A, D'Erasmo E, Tancredi A, Minisola S

Calcified tissue international10 Sept 2009Cited by 6 (Europe PMC)

PMID19756348DOI10.1007/s00223-009-9280-4PepBankPUB-19756348

Publisher page PubMedAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanNon-randomized trialActivity measurement
In postmenopausal osteoporotic women previously treated with bisphosphonates, ionized calcium changes did not differ between PTH(1-34) and PTH(1-84).
In plain wordsIn women with osteoporosis previously treated with bisphosphonates, blood calcium changes did not differ between teriparatide and PTH(1-84).
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerum ionized calcium changes
Study
n = 10
Comparator
PTH(1-84)
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 mcgAs given in this study (human).
Source sentences
Summary
The PTH peptides did not differ with respect to changes in Ca(2+) at 2, 4, and 24 h postinjection; at the last time point the values were virtually identical to the initial values.
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated the frequency of hypercalcemia and/or hypercalciuria following parathyroid hormone (PTH) 1-34 and 1-84 administration in a crossover trial. Ten postmenopausal osteoporotic women previously treated with bisphosphonates were subdivided into two groups of five patients each.
Summary · context
Thereafter, 100 mcg of PTH(1-84) or 20 mcg of PTH(1-34) was administered.
Report a problemFND-1975634801
02HumanNon-randomized trialActivity measurement
In postmenopausal osteoporotic women, ionized calcium at 24 hours after PTH(1-34) was virtually identical to baseline.
In plain wordsIn women with osteoporosis, blood calcium was approximately at baseline 24 hours after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerum ionized calcium at 24 hours
Study
n = 10
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 mcgAs given in this study (human).
Source sentences
Summary
The PTH peptides did not differ with respect to changes in Ca(2+) at 2, 4, and 24 h postinjection; at the last time point the values were virtually identical to the initial values.
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated the frequency of hypercalcemia and/or hypercalciuria following parathyroid hormone (PTH) 1-34 and 1-84 administration in a crossover trial. Ten postmenopausal osteoporotic women previously treated with bisphosphonates were subdivided into two groups of five patients each.
Summary · context
Thereafter, 100 mcg of PTH(1-84) or 20 mcg of PTH(1-34) was administered.
Report a problemFND-1975634802
03HumanNon-randomized trialActivity measurement
In postmenopausal osteoporotic women, urinary calcium (Ca/Cr ratio and Ca excretion) did not differ from baseline the day after PTH(1-34).
In plain wordsIn women with osteoporosis, urine calcium did not change from baseline the day after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeUrinary calcium excretion (Ca/Cr ratio and Ca excretion)
Study
n = 10
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 mcgAs given in this study (human).
Source sentences
Summary
There was no difference in urinary Ca on the day following PTH injection compared to baseline, in terms both of Ca/Cr and of Ca excretion.
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated the frequency of hypercalcemia and/or hypercalciuria following parathyroid hormone (PTH) 1-34 and 1-84 administration in a crossover trial. Ten postmenopausal osteoporotic women previously treated with bisphosphonates were subdivided into two groups of five patients each.
Summary · context
Thereafter, 100 mcg of PTH(1-84) or 20 mcg of PTH(1-34) was administered.
Report a problemFND-1975634803
04HumanNon-randomized trialActivity measurement
In postmenopausal osteoporotic women, vitamin D metabolite changes did not differ between PTH(1-34) and PTH(1-84).
In plain wordsIn women with osteoporosis, active vitamin D changes did not differ between teriparatide and PTH(1-84).
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerum 1,25-dihydroxyvitamin D changes
Study
n = 10
Comparator
PTH(1-84)
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 mcgAs given in this study (human).
Measurements
1,25(OH)(2)D
124.1 pg/ml
PTH(1-34), 24 hours
Increase from baseline
130%
PTH(1-34), 24 hours
1,25(OH)(2)D
125.6 pg/ml
PTH(1-84), 24 hours
Increase from baseline
153%
PTH(1-84), 24 hours
Source sentences
Summary
The two PTH peptides did not differ with respect to changes in 1,25(OH)(2)D at 2, 4, and 24 h considering both the absolute values and the percent changes with respect to baseline (24-h 1-84 = 125.6 + or - 58.6 pg/ml, 153% increase; 1-34 = 124.1 + or - 64.7, 130%).
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated the frequency of hypercalcemia and/or hypercalciuria following parathyroid hormone (PTH) 1-34 and 1-84 administration in a crossover trial. Ten postmenopausal osteoporotic women previously treated with bisphosphonates were subdivided into two groups of five patients each.
Summary · context
Thereafter, 100 mcg of PTH(1-84) or 20 mcg of PTH(1-34) was administered.
Report a problemFND-1975634805
05HumanNon-randomized trialActivity measurement
In postmenopausal osteoporotic women previously treated with bisphosphonates, serum 1,25-dihydroxyvitamin D increased by 130% from baseline 24 hours after PTH(1-34).
In plain wordsIn women with osteoporosis previously treated with bisphosphonates, active vitamin D increased from baseline 24 hours after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum 1,25-dihydroxyvitamin D increase at 24 hours
Study
n = 10
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 mcgAs given in this study (human).
Measurements
1,25(OH)(2)D
124.1 pg/ml
PTH(1-34), 24 hours
Increase from baseline
130%
PTH(1-34), 24 hours
Source sentences
Summary
The two PTH peptides did not differ with respect to changes in 1,25(OH)(2)D at 2, 4, and 24 h considering both the absolute values and the percent changes with respect to baseline (24-h 1-84 = 125.6 + or - 58.6 pg/ml, 153% increase; 1-34 = 124.1 + or - 64.7, 130%).
2 context sentences(design, population, supporting numbers)
Summary · context
We investigated the frequency of hypercalcemia and/or hypercalciuria following parathyroid hormone (PTH) 1-34 and 1-84 administration in a crossover trial. Ten postmenopausal osteoporotic women previously treated with bisphosphonates were subdivided into two groups of five patients each.
Summary · context
Thereafter, 100 mcg of PTH(1-84) or 20 mcg of PTH(1-34) was administered.
Report a problemFND-1975634806
06HumanNon-randomized trialSafety outcome
In postmenopausal osteoporotic women, PTH(1-84) and PTH(1-34) did not differ in ionized calcium changes at 2, 4, and 24 hours.
In plain wordsIn osteoporotic women, PTH(1-84) and PTH(1-34) did not differ in ionized calcium changes.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeSerum ionized calcium changes
Study
n = 10
Comparator
PTH(1-34)
Outcome group
Calcium Metabolism · Endocrine and hormones
Studied dose
100 mcg · injection · single doseAs given in this study (human).
Source sentences
Summary
The PTH peptides did not differ with respect to changes in Ca(2+) at 2, 4, and 24 h postinjection;
5 context sentences(design, population, supporting numbers)
Summary · context
We investigated the frequency of hypercalcemia and/or hypercalciuria following parathyroid hormone (PTH) 1-34 and 1-84 administration in a crossover trial.
Summary · context
Ten postmenopausal osteoporotic women previously treated with bisphosphonates were subdivided into two groups of five patients each.
Summary · context
Thereafter, 100 mcg of PTH(1-84) or 20 mcg of PTH(1-34) was administered.
Summary · context
A 24-h urinary collection and blood samples 2, 4, and 24-h after each PTH administration were again taken.
Summary · context
One week after the first PTH administration patients were rechallenged with the second PTH.
Report a problemFND-1975634807
07HumanNon-randomized trialSafety outcome
In postmenopausal osteoporotic women, ionized calcium after PTH(1-84) was virtually identical to baseline at 24 hours.
In plain wordsIn osteoporotic women, ionized calcium after PTH(1-84) was virtually identical to baseline at 24 hours.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
Direction not reportedSerum ionized calcium at 24 hours
Study
n = 10
Comparator
Baseline
Outcome group
Calcium Metabolism · Endocrine and hormones
Studied dose
100 mcg · injection · single doseAs given in this study (human).
Source sentences
Summary
The PTH peptides did not differ with respect to changes in Ca(2+) at 2, 4, and 24 h postinjection; at the last time point the values were virtually identical to the initial values.
5 context sentences(design, population, supporting numbers)
Summary · context
We investigated the frequency of hypercalcemia and/or hypercalciuria following parathyroid hormone (PTH) 1-34 and 1-84 administration in a crossover trial.
Summary · context
Ten postmenopausal osteoporotic women previously treated with bisphosphonates were subdivided into two groups of five patients each.
Summary · context
Thereafter, 100 mcg of PTH(1-84) or 20 mcg of PTH(1-34) was administered.
Summary · context
A 24-h urinary collection and blood samples 2, 4, and 24-h after each PTH administration were again taken.
Summary · context
One week after the first PTH administration patients were rechallenged with the second PTH.
Report a problemFND-1975634808
08HumanNon-randomized trialSafety outcome
In postmenopausal osteoporotic women, urinary calcium-to-creatinine ratio did not differ from baseline the day after PTH(1-84).
In plain wordsIn osteoporotic women, urinary calcium-to-creatinine ratio did not differ from baseline the day after PTH(1-84).
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeUrinary calcium-to-creatinine ratio
Study
n = 10
Comparator
Baseline
Outcome group
Calcium Metabolism · Endocrine and hormones
Studied dose
100 mcg · injection · single doseAs given in this study (human).
Source sentences
Summary
There was no difference in urinary Ca on the day following PTH injection compared to baseline, in terms both of Ca/Cr and of Ca excretion.
5 context sentences(design, population, supporting numbers)
Summary · context
We investigated the frequency of hypercalcemia and/or hypercalciuria following parathyroid hormone (PTH) 1-34 and 1-84 administration in a crossover trial.
Summary · context
Ten postmenopausal osteoporotic women previously treated with bisphosphonates were subdivided into two groups of five patients each.
Summary · context
Thereafter, 100 mcg of PTH(1-84) or 20 mcg of PTH(1-34) was administered.
Summary · context
A 24-h urinary collection and blood samples 2, 4, and 24-h after each PTH administration were again taken.
Summary · context
One week after the first PTH administration patients were rechallenged with the second PTH.
Report a problemFND-1975634809
09HumanNon-randomized trialSafety outcome
In postmenopausal osteoporotic women, urinary calcium excretion did not differ from baseline the day after PTH(1-84).
In plain wordsIn osteoporotic women, urinary calcium excretion did not differ from baseline the day after PTH(1-84).
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeUrinary calcium excretion
Study
n = 10
Comparator
Baseline
Outcome group
Calcium Metabolism · Endocrine and hormones
Studied dose
100 mcg · injection · single doseAs given in this study (human).
Source sentences
Summary
There was no difference in urinary Ca on the day following PTH injection compared to baseline, in terms both of Ca/Cr and of Ca excretion.
5 context sentences(design, population, supporting numbers)
Summary · context
We investigated the frequency of hypercalcemia and/or hypercalciuria following parathyroid hormone (PTH) 1-34 and 1-84 administration in a crossover trial.
Summary · context
Ten postmenopausal osteoporotic women previously treated with bisphosphonates were subdivided into two groups of five patients each.
Summary · context
Thereafter, 100 mcg of PTH(1-84) or 20 mcg of PTH(1-34) was administered.
Summary · context
A 24-h urinary collection and blood samples 2, 4, and 24-h after each PTH administration were again taken.
Summary · context
One week after the first PTH administration patients were rechallenged with the second PTH.
Report a problemFND-1975634810
10HumanNon-randomized trialActivity measurement
In osteoporotic women, PTH(1-84) and PTH(1-34) did not differ in absolute vitamin D metabolite values at 2, 4, and 24 hours.
In plain wordsIn osteoporotic women, PTH(1-84) and PTH(1-34) did not differ in absolute vitamin D metabolite values.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeAbsolute 1,25-dihydroxyvitamin D
Study
n = 10
Comparator
PTH(1-34)
Outcome group
Calcium Metabolism · Endocrine and hormones
Studied dose
100 mcg · injection · single doseAs given in this study (human).
Measurements
1,25(OH)(2)D
125.6 pg/ml
24-h PTH(1-84)
Variability
58.6 pg/ml
24-h PTH(1-84), plus or minus
1,25(OH)(2)D
124.1 pg/ml
24-h PTH(1-34)
Variability
64.7 pg/ml
24-h PTH(1-34), plus or minus
Source sentences
Summary
The two PTH peptides did not differ with respect to changes in 1,25(OH)(2)D at 2, 4, and 24 h considering both the absolute values and the percent changes with respect to baseline (24-h 1-84 = 125.6 + or - 58.6 pg/ml, 153% increase; 1-34 = 124.1 + or - 64.7, 130%).
5 context sentences(design, population, supporting numbers)
Summary · context
We investigated the frequency of hypercalcemia and/or hypercalciuria following parathyroid hormone (PTH) 1-34 and 1-84 administration in a crossover trial.
Summary · context
Ten postmenopausal osteoporotic women previously treated with bisphosphonates were subdivided into two groups of five patients each.
Summary · context
Thereafter, 100 mcg of PTH(1-84) or 20 mcg of PTH(1-34) was administered.
Summary · context
A 24-h urinary collection and blood samples 2, 4, and 24-h after each PTH administration were again taken.
Summary · context
One week after the first PTH administration patients were rechallenged with the second PTH.
Report a problemFND-1975634811
11HumanNon-randomized trialActivity measurement
In osteoporotic women, PTH(1-84) and PTH(1-34) did not differ in vitamin D metabolite percent changes at 2, 4, and 24 hours.
In plain wordsIn osteoporotic women, PTH(1-84) and PTH(1-34) did not differ in vitamin D metabolite percent changes.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant change1,25-dihydroxyvitamin D percent change
Study
n = 10
Comparator
PTH(1-34)
Outcome group
Calcium Metabolism · Endocrine and hormones
Studied dose
100 mcg · injection · single doseAs given in this study (human).
Measurements
1,25(OH)(2)D increase
153%
24-h PTH(1-84)
1,25(OH)(2)D increase
130%
24-h PTH(1-34)
Source sentences
Summary
The two PTH peptides did not differ with respect to changes in 1,25(OH)(2)D at 2, 4, and 24 h considering both the absolute values and the percent changes with respect to baseline (24-h 1-84 = 125.6 + or - 58.6 pg/ml, 153% increase; 1-34 = 124.1 + or - 64.7, 130%).
5 context sentences(design, population, supporting numbers)
Summary · context
We investigated the frequency of hypercalcemia and/or hypercalciuria following parathyroid hormone (PTH) 1-34 and 1-84 administration in a crossover trial.
Summary · context
Ten postmenopausal osteoporotic women previously treated with bisphosphonates were subdivided into two groups of five patients each.
Summary · context
Thereafter, 100 mcg of PTH(1-84) or 20 mcg of PTH(1-34) was administered.
Summary · context
A 24-h urinary collection and blood samples 2, 4, and 24-h after each PTH administration were again taken.
Summary · context
One week after the first PTH administration patients were rechallenged with the second PTH.
Report a problemFND-1975634812
12HumanNon-randomized trialActivity measurement
In osteoporotic women, 1,25-dihydroxyvitamin D increased 153% from baseline at 24 hours after PTH(1-84).
In plain wordsIn osteoporotic women, the vitamin D metabolite increased 153% from baseline at 24 hours after PTH(1-84).
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
Increase1,25-dihydroxyvitamin D increase at 24 hours
Study
n = 10
Comparator
Baseline
Outcome group
Calcium Metabolism · Endocrine and hormones
Studied dose
100 mcg · injection · single doseAs given in this study (human).
Measurements
1,25(OH)(2)D increase
153%
24-h PTH(1-84)
Source sentences
Summary
The two PTH peptides did not differ with respect to changes in 1,25(OH)(2)D at 2, 4, and 24 h considering both the absolute values and the percent changes with respect to baseline (24-h 1-84 = 125.6 + or - 58.6 pg/ml, 153% increase; 1-34 = 124.1 + or - 64.7, 130%).
5 context sentences(design, population, supporting numbers)
Summary · context
We investigated the frequency of hypercalcemia and/or hypercalciuria following parathyroid hormone (PTH) 1-34 and 1-84 administration in a crossover trial.
Summary · context
Ten postmenopausal osteoporotic women previously treated with bisphosphonates were subdivided into two groups of five patients each.
Summary · context
Thereafter, 100 mcg of PTH(1-84) or 20 mcg of PTH(1-34) was administered.
Summary · context
A 24-h urinary collection and blood samples 2, 4, and 24-h after each PTH administration were again taken.
Summary · context
One week after the first PTH administration patients were rechallenged with the second PTH.
Report a problemFND-1975634813

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:37 UTC
Study data updated · source update from Europe PMC
Version 2
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.